ATA Inc. Stock News

atai Life Sciences N.V. (ATAI) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.

Atai Life Sciences is advancing RL-007 for the treatment of cognitive impairment associated with schizophrenia, with top-line results expected in the 2nd half of 2024. The company is also working on a

atai Life Sciences N.V. (ATAI) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.

Alex Carchidi returns to update investors on the psychedelics industry. Collapse, consolidation, and why you shouldn't bet on just 1 stock.

COMPASS: The Landscape Is Changing Quickly; Risk Is Up And Potential Down

The U.S. Food and Drug Administration on Friday issued its first draft guidance on psychedelic drug clinical trials, outlining considerations for companies investigating the drugs' potential to treat

Blake Mycoskie, founder of the canvas-footwear phenomenon TOMS Shoes, has committed to giving $100 million to support psychedelic research and access, Mycoskie told MarketWatch in an exclusive intervi

When it comes to investing, penny stocks often evoke a sense of intrigue and opportunity. These low-priced securities, typically traded under $5 per share, can potentially deliver substantial gains qu

NEW YORK and BERLIN, May 02, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health dis

Atai's stock probably isn't going to spike by as much as Wall Street says. It has enough money for the next few years, and it could still raise even more.

Atai focuses on psychedelics to treat mental illnesses. The clinical-stage biopharmaceutical company said it has enough cash to last into 2026.

In its 2022 Q4 report, Atai reiterated that it is well capitalized, with a cash runway into the first half of 2026. Its sound financial position and deep clinical pipeline appear to have sparked a wav

The psychedelic drug boom may be taking off, but one company in the space is trimming its workforce. Atai Life Sciences (NASDAQ: ATAI ) just announced it has laid off roughly 30% of its staff.

Psychedelic stocks have seen remarkable progress in recent years, evolving from a fad to mainstream medicine. Several pharmaceutical companies are now investigating their potential therapeutic value.

atai Life Sciences N.V. (ATAI) is technically in oversold territory now, so the heavy selling pressure might have exhausted.